NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

We definitely have different beliefs, I think NICE will consider the use of Poly-ICLC with DCVax-L and therefore see a far greater percentage of patients seeing a major improvement. Furthermore by the end of this year, or early next at the latest, I believe the EDEN will be accepted by the regulators for production.

When you look only at 5 year data you're not seeing substantial benefits to those who don't live 5 years. I've known a few pancreatic cancer patients who very much enjoyed most of the 2 to 3 years they were given with treatment, it probably would have been well under a year without it. While I've not known GBM patients, I believe much the same applies to GBM.

Of course when you add Poly-ICLC 50% are living to, or beyond 5 years. I suspect that many who don't live 5 years will be living to near that point, but more data is really needed. Frankly I think that the crew at UCLA in a larger trial may actually be able to take 5 year survival to closer to 60% or even 70%. Frankly the more they learn about treatment with the vaccine and other therapeutics the greater percentage that will live and the longer they'll live.

Gary